Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome.

Literature DB >> 29268473

EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome.

Andreas Tiefenbacher¹, Robert Pirker¹.

Abstract

Entities: Disease Gene

Year: 2017 PMID： 29268473 PMCID： PMC5720983 DOI： 10.21037/jtd.2017.10.02

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

17 in total

1. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Authors: Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Keunchil Park; Filippo de Marinis; Wilfried E E Eberhardt; Luis Paz-Ares; Stephan Störkel; Karl-Maria Schumacher; Anja von Heydebreck; Ilhan Celik; Kenneth J O'Byrne
Journal: Lancet Oncol Date: 2011-11-04 Impact factor: 41.316

2. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.

Authors: Lin-Hung Wei; Min-Liang Kuo; Chi-An Chen; Chia-Hung Chou; Kuo-Bau Lai; Chien-Nan Lee; Chang-Yao Hsieh
Journal: Oncogene Date: 2003-03-13 Impact factor: 9.867

3. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Authors: Jean-Louis Pujol; Robert Pirker; Thomas J Lynch; Charles A Butts; Rafael Rosell; Frances A Shepherd; Johan Vansteenkiste; Kenneth J O'Byrne; Barbara de Blas; Jim Heighway; Anja von Heydebreck; Nick Thatcher
Journal: Lung Cancer Date: 2013-11-16 Impact factor: 5.705

4. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors: Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal: Clin Cancer Res Date: 2010-12-06 Impact factor: 12.531

5. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

Authors: Weiwen Fan; Zhe Tang; Lihong Yin; Bei Morrison; Said Hafez-Khayyata; Pingfu Fu; Honglian Huang; Rakesh Bagai; Shan Jiang; Adam Kresak; Scott Howell; Amit Vasanji; Chris A Flask; Balazs Halmos; Henry Koon; Patrick C Ma
Journal: Cancer Res Date: 2011-05-09 Impact factor: 12.701

6. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245

7. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544

8. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors: Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal: Lancet Oncol Date: 2014-08-27 Impact factor: 41.316

9. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors: Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal: Lancet Date: 2009-05-02 Impact factor: 79.321

5. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.

Authors: Cong Xu; Xiaojun Yao; Ting Li; Jue Wang; Bo An; Jing Wang; Xinbing Sui; Elaine Lai-Han Leung; Qibiao Wu
Journal: Transl Cancer Res Date: 2020-04 Impact factor: 1.241

5 in total

EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome.

1. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

2. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.

3. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

4. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

5. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

6. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

7. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

8. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

9. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

10. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

1. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.

Review 2. YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.

Review 3. Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

Review 4. Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models.

5. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.